Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Blood Pressure Imbalances and Circulatory Shock01:24

Blood Pressure Imbalances and Circulatory Shock

1.3K
Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
1.3K
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

353
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
353
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

300
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
300
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

178
Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
178
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

157
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
157
Cardiopulmonary Resuscitation I: Adult01:21

Cardiopulmonary Resuscitation I: Adult

411
Cardiopulmonary resuscitation, or CPR, is a life-saving emergency procedure performed when a person's heart has stopped beating or they are no longer breathing. The foundation of CPR is Basic Life Support (BLS), which focuses on the early recognition of cardiac arrest, the immediate start of high-quality chest compressions, and the timely use of an automated external defibrillator (AED).Assessing Responsiveness and Checking the Carotid PulseWhen approaching an unresponsive person, first ensure...
411

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

60 years of ARDS and the evolution of extracorporeal lung support - from ECMO to ECCO<sub>2</sub>R.

Intensive care medicine·2026
Same author

ECMO for patients with obesity: evidence and practice.

Intensive care medicine·2026
Same author

How to optimize brain perfusion and prevent cerebral complications during extracorporeal life support.

Intensive care medicine·2026
Same author

Palliative and End-of-Life Care Utilization in Cardiogenic Shock Complicating Acute Myocardial Infarction: A Population-Based Study.

JACC. Advances·2026
Same author

Long-term quality of life and functional outcomes in extracorporeal membrane oxygenation survivors.

JHLT open·2026
Same author

Visual Right Ventricular Assessment in ICU: A Multicenter International Study.

Critical care medicine·2026

関連する実験動画

Updated: Dec 14, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.5K

心臓発作性ショックに対する一時的な循環支援

Alain Combes1, Susanna Price2, Arthur S Slutsky3

  • 1Sorbonne Université, Institute of Cardiometabolism and Nutrition, Paris, France; Service de Médecine Intensive-Réanimation, Höpitaux Universitaires Pitié Salpêtrière, Assistance Publique-Höpitaux de Paris, Institut de Cardiologie, Paris, France.

Lancet (London, England)
|July 20, 2020
PubMed
まとめ

血管圧縮薬とイノトロプ薬の代替として,一時的な循環支援システムは,心血管性ショック管理に役立ちます. このレビューでは,それらの生理学的根拠,証拠,および倫理的検討を考察します.

さらに関連する動画

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.9K
The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

23.8K

関連する実験動画

Last Updated: Dec 14, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.5K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.9K
The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

23.8K

科学分野:

  • 心臓病科
  • 心血管医学
  • 医療機器

背景:

  • 心臓発作は急性心疾患や進行した心疾患に起因する.
  • 血管圧縮薬やイノトロプのような現在の治療には,心筋の酸素需要の増加や輸血障害など,限界があります.
  • 機械的な一時的な循環支援システムは,コストと証拠のギャップにもかかわらず,ますます使用されています.

研究 の 目的:

  • 心臓発作性ショックにおける一時的な循環支援の生理学的根拠を見直す.
  • これらのデバイスの指示と禁忌に関する証拠を評価する.
  • 倫理的検討と将来の研究ニーズについて議論する.

主な方法:

  • 心臓発作ショックにおける一時的な循環支援システムの文献レビュー
  • 生理学的原理と臨床的証拠の分析
  • 倫理的な影響と研究上のギャップの検討

主要な成果:

  • 血液循環を一時的にサポートすることで 心臓のパウントが増加し 薬剤の代替品となるのです
  • 特定の徴候と禁忌を裏付ける証拠は限られている.
  • 重要な倫理的考慮事項と高品質の研究の必要性があります.

結論:

  • 循環器を一時的に支えるのは 心臓発作性ショックの 複雑で成長する選択肢です
  • 最適な使用,有効性,安全性を確立するには,さらなる研究が不可欠です.
  • 臨床の意思決定において 利益とリスクと倫理的な懸念のバランスが 極めて重要です